Novel interaction between HPV E6 and BARD1 (BRCA1-associated ring domain 1) and its biologic roles

DNA and Cell Biology

Volumn 26, Issue 10, 2007, Pages 753-761

  Yim, Eun Kyoung ^a   Lee, Keun Ho ^a   Myeong, Jin ^a   Tong, Seo Yun ^b   Um, Soo Jong ^c   Park, Jong Sup ^a  

^a The Catholic University of Korea   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Sejong University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN E6; PROTEIN P53; BARD1 PROTEIN, HUMAN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; AMINO ACID SEQUENCE; ANIMAL; CERCOPITHECUS; FEMALE; METABOLISM; MOLECULAR GENETICS; TRANSACTIVATION; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS;

EID: 38449109508     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2007.0588     Document Type: Article

References (29)

1. Boyer, S.N., Wazer, D.E., and Band, V. (1996). E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56, 4620-4624.
2. Brzovic, P.S., Meza, J.E., King, M.C., and Klevit, R.E. (2001). BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J. Biol. Chem. 276, 41399-41406.
3. Chiba, N., and Parvin, J.D. (2001). Redistribution of BRCA1 among four different protein complexes following replication blockage. J. Biol. Chem. 276, 38549-38554.
4. Crook, T., Tidy, J.A., and Vousden, K.H. (1991). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67, 547-556.
5. Dechend, R., Hirano, F., Lehmann, K., Heissmeyer, V., Ansieau, S., Wulczyn, F.G., Scheidereit, C., and Leutz, A. (1999). The Bel-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18, 3316-3323.
6. Dyson, N., Howley, P.M., Munger, K., and Harlow, E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-940.
7. Ghimenti, C., Sensi, E., Presciuttini, S., Brunetti, I.M., Conte, P., Bevilacqua, G., and Caligo, M.A. (2002). Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes Cancer 33, 235-242.
8. Hansen, R., and Oren, M. (1997). p53: from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7, 46-51.
9. Hofmann, T.G., Mincheva, A., Lichter, P., Droge, W., and Schmitz, M.L. (2000). Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34. Biochimie 82, 1123-1127.
10. Huibregtse, J.M., Scheffner, M., and Howley, P.M. (1993). Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 13, 775-784.
11. Irminger-Finger, I., Leung, W.C., Li, J., Dubois-Dauphin, M., Harb, J., Feki, A., Jefford, C.E., Soriano, J.V., Jaconi, M., Montesano, R., and Krause, K.H. (2001). Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol. Cell 8, 1255-1266.
12. Irminger-Finger, I., Soriano, J.V., Vaudan, G., Montesano, R., and Sappino, A.P. (1998). In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells. J. Cell Biol. 143, 1329-1339.
13. Jang, E.R., and Lee, J.S. (2004). DNA damage response mediated through BRCA1. Cancer Res. Treat. 36, 214-221.
14. Jin, Y., Xu, X.L., Yang, M.C., Wei, F., Ayi, T.C., Bowcock, A.M., and Baer, R. (1997). Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc. Natl. Acad. Sci. USA 94, 12075-12080.
15. Kanda, T., Watanabe, S., Zanma, S., Sato, H., Furuno, A., and Yoshike, K. (1991). Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology 185, 536-543.
16. Kleiman, F.E., and Manley, J.L. (2001). The BARD1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression. Cell 104, 743-753.
17. 2+-binding fragment from the human papillomavirus type 16 E6 protein. Biochemistry 40, 1196-1204.
18. Mantovani, F., and Banks, L. (2001). The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20, 7874-7887.
19. Morris, J.R., Keep, N.H., and Solomon, E. (2002). Identification of residues required for the interaction of BARD1 with BRCA1. J. Biol. Chem. 277, 9382-9386.
20. Nakagawa, S., Watanabe, S.S., Yoshikawa, H., Takentani, Y., Yoshiike, K., and Kanda, T. (1995). Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212, 535-542.
21. Park, J.S., Kim, E.J., Kwon, H.J., Hwang, E.S., Namkoong, S.E., and Um, S.J. (2000). Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275, 6764-6769.
22. Park, J.S., Kim, E.J., Lee, J.Y., Sin, H.S., Namkoong, S.E., and Um, S.J. (2001). Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int. J. Cancer 91, 822-827.
23. Patel, D., Huang, S.M., Baglia, L.A., and Mccance, D.J. (1999). The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18, 5061-5072.
24. Pim, D., Storey, A., Thomas, M., Massimi, P., and Banks, L. (1994). Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9, 1869-1876.
25. Qin, J.Z., Chaturvedi, V., Denning, M.F., Choubey, D., Diaz, M.O., and Nickoloff, B.J. (1999). Role of NF-kappaB in the apoptotic-resistant phenotype of keratinocytes. J. Biol. Chem. 274, 37957-37964.
26. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd edition (Cold Spring Harbor Laboratory Press, New York).
27. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., and Howley, P.M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
28. Sedgwick, S.G., and Smerdon, S.J. (1999). The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem. Sci. 24, 311-316.
29. Wu, L.C., Wang, Z.W., Tsan, J.T., Spillman, M.A., Phung, A., Xu, K.L., Yang, M.C., Hwang, L.Y., Bowcock, A.M., and Baer, R. (1996). Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14, 430-440.